Brokers Issue Forecasts for Sanara MedTech FY2026 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Sanara MedTech in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn ($1.65) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $46.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The firm had revenue of $23.43 million during the quarter, compared to the consensus estimate of $23.48 million.

Separately, HC Wainwright upped their price objective on shares of Sanara MedTech from $51.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, May 15th.

Sanara MedTech Trading Down 0.9%

NASDAQ:SMTI opened at $28.69 on Wednesday. The firm’s fifty day moving average is $30.39 and its 200-day moving average is $32.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech has a 52 week low of $25.86 and a 52 week high of $39.08. The firm has a market cap of $255.00 million, a P/E ratio of -28.98 and a beta of 1.35.

Institutional Investors Weigh In On Sanara MedTech

A number of large investors have recently bought and sold shares of SMTI. Marshall Wace LLP acquired a new stake in Sanara MedTech in the fourth quarter worth $1,005,000. Renaissance Technologies LLC grew its holdings in Sanara MedTech by 152.9% in the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company’s stock worth $1,175,000 after purchasing an additional 21,400 shares during the period. Nuveen LLC acquired a new stake in Sanara MedTech in the first quarter worth $326,000. JPMorgan Chase & Co. grew its holdings in Sanara MedTech by 234.5% in the fourth quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company’s stock worth $451,000 after purchasing an additional 9,516 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Sanara MedTech by 116.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 15,925 shares of the company’s stock valued at $529,000 after buying an additional 8,567 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors and hedge funds.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.